Clinical Trial Update: Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy [Phase 4]

View source ↗

Summary

Phase 4 safety update evaluating Viracept (nelfinavir) 625 mg in HIV-infected pregnant women. The trial was sponsored by Pfizer and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Viracept (Nelfinavir)

Snippet

Sponsor: Pfizer | Conditions: HIV Infection | Phase 4 | Status: COMPLETED